MBIO (Mustang Bio) Beta: 2.8121 (As of Jun. 24, 2026)


MBIO Mustang Bio Inc MBIO
32 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is Mustang Bio Beta?

Mustang Bio MBIO +3.38% 32 Beta is 2.8121 as of Jun. 24, 2026. GuruFocus rates MBIO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Mustang Bio's Beta is 2.8121.


Mustang Bio  (NAS:MBIO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Mustang Bio Beta Related Terms


Mustang Bio Beta Historical Data

* Premium members only.

The historical data trend for Mustang Bio's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mustang Bio Beta Chart

Mustang Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.36 1.41 1.58 2.24 3.69

Mustang Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.19 2.56 3.39 3.69 2.85

MBIO vs ADIL, PULM, CDT: Beta Comparison

For the Biotechnology subindustry, Mustang Bio's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mustang Bio Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mustang Bio's Beta distribution charts can be found below:

* The bar in red indicates where Mustang Bio's Beta falls into.


MBIO
32GF Score
Mustang Bio Inc MBIO
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mustang Bio Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.8121 mean?
Mustang Bio (MBIO) has a Beta of 2.8121 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Mustang Bio and its competitors.
Is Mustang Bio's Beta too high?
Mustang Bio's current Beta is 2.8121. Overall, Mustang Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Mustang Bio's Beta compare to ADIL and PULM?
Mustang Bio's Beta of 2.8121 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Mustang Bio and its competitors. Mustang Bio's current Beta is 2.8121. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mustang Bio stock overvalued right now?
Mustang Bio (MBIO) has a current Beta of 2.8121. The current Beta is 2.8121. Mustang Bio's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Mustang Bio (MBIO), the current Beta is 2.8121 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mustang Bio Business Description

Address 95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
32GF Score

Get the complete analysis for MBIO

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price